Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
32.1M
-
Shares change
-
+662K
-
Total reported value, excl. options
-
$1.77B
-
Value change
-
+$33.4M
-
Put/Call ratio
-
3.56
-
Number of buys
-
76
-
Number of sells
-
-69
-
Price
-
$54.98
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q1 2022
188 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q1 2022.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.1M shares
of 53M outstanding shares and own 60.53% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (5.42M shares), WELLINGTON MANAGEMENT GROUP LLP (3.66M shares), VANGUARD GROUP INC (2.93M shares), BlackRock Inc. (2.37M shares), JPMORGAN CHASE & CO (2.1M shares), 683 Capital Management, LLC (1.57M shares), Alua Capital Management LP (1.34M shares), KPS Global Asset Management UK Ltd (1.22M shares), BAILLIE GIFFORD & CO (1.06M shares), and JS Capital Management LLC (807K shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.